Grufity logo
Grufity logo
SLS

SLS - SELLAS Life Sciences Group Inc Stock Price, Fair Value and News

$7.53-0.20 (-2.59%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

7/100

SLS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

7/100

SLS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SLS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLS Price Action

Last 7 days

-3.3%

Last 30 days

9.0%

Last 90 days

53.2%

Trailing 12 Months

365.1%

SLS RSI Chart

SLS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLS Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-46.35

Price/Sales (Trailing)

1.7K

EV/EBITDA

-38.66

Price/Free Cashflow

-48.48

SLS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SLS Fundamentals

SLS Revenue

Revenue (TTM)

1.0M

SLS Earnings

Earnings (TTM)

-29.5M

Earnings Growth (Yr)

-44.62%

Earnings Growth (Qtr)

-9.78%

SLS Profitability

Operating Margin

-58.60%

EBT Margin

-4130.10%

Return on Equity

-27.42%

Return on Assets

-25.8%

Free Cashflow Yield

-2.06%

SLS Investor Care

Shares Dilution (1Y)

99.49%

Diluted EPS (TTM)

-0.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20222.9M1.0M1.0M1.0M
20213.3M4.8M6.2M7.6M
2020---1.9M
2019----
2018----
2017----
2016-17.6M--
20159.9M10.9M--
20149.3M9.3M9.3M9.3M
2013-7.0M7.4M9.3M
2012----
2011----
2010----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About SELLAS Life Sciences Group Inc

SLS
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.
 CEO
 WEBSITEsellaslifesciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES17

SELLAS Life Sciences Group Inc Frequently Asked Questions

SLS is the stock ticker symbol of SELLAS Life Sciences Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of SELLAS Life Sciences Group Inc is 1.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, SLS's PE ratio (Price to Earnings) is -47.58 and Price to Sales (PS) ratio is 1.69 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, SELLAS Life Sciences Group Inc has provided -0.596 (multiply by 100 for percentage) rate of return.